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Background: Refractory anemia and refractory anemia with ringed sideroblasts are two myelodysplastic syndrome
(MDS) subgroups linked with anemia. MDS is a group of heterogeneous oncohematological bone marrow disorders
characterized by ineffective hematopoiesis, blood cytopenias, and progression of the disease toward acute myeloid
leukemia. The aim of this study was to search for plasma proteome changes in MDS patients with refractory anemia
and refractory anemia with ringed sideroblasts.
Results: A total of 26 patient and healthy donor plasma samples were depleted of fourteen high-abundant plasma
proteins, separated with 2D electrophoresis, and statistically processed with Progenesis SameSpots software. 55
significantly differing spots were observed and corresponded to 39 different proteins identified by nanoLC-MS/MS.
Changes in the fragments of the inter-alpha-trypsin inhibitor heavy chain H4 protein were observed. Using mass
spectrometry-based relative label-free quantification of tryptic peptides, there were differences in alpha-2-HS-
glycoprotein peptides, while no differences were observed between the control and patient sample groups for
retinol-binding protein 4 peptides.
Conclusions: This study describes plasma proteome changes associated with MDS patients with refractory anemia
and refractory anemia with ringed sideroblasts. Changes observed in the inter-alpha-trypsin inhibitor heavy chain
H4 fragments were in agreement with our previous studies of other MDS subgroups: refractory cytopenia with
multilineage dysplasia and refractory anemia with excess blasts subtype 1. Mass spectrometry-based relative
quantification of retinol-binding protein 4 peptides has shown that there are differences in the modification of this
protein between refractory anemia with excess blasts subtype 1 patients and MDS patients with refractory anemia
and refractory anemia with ringed sideroblasts. Alpha-2-HS-glycoprotein seems to be a new potential MDS
biomarker candidate.
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Anemia, one of the most common blood disorders, is
usually caused by the decrease of red blood cells. Thus,
the oxygen-carrying capacity of the blood is decreased,
and anemic patients consequently feel tired and suffer
from other consequences of hypoxia. As one of the most
common causes of anemia is bleeding, an iron defi-
ciency, underproduction, or excessive destruction of red
blood cells also occur.
Refractory anemia (RA) and refractory anemia with
ringed sideroblasts (RARS) are two myelodysplastic syn-
drome (MDS) subgroups linked with anemia, according
to the World Health Organization (WHO) classification
of MDS [1]. Both RA and RARS are characterized by
dysplasia limited only to the erythroid lineage; by less
than 5% of blasts located in the bone marrow, and with
limited response of the anemia to treatment.
Very little is known about plasma protein alterations oc-
curring in myelodysplastic syndrome. Even though there
are several proteomic studies dealing with MDS [2-4],
including our previous studies of refractory cytopenia with
multilineage dysplasia (RCMD) [5] and refractory anemia
with excess blasts subtype 1 (RAEB-1) [6], there is still a
lack of data from different MDS subgroups that would
enable comparison of these subgroups. The possibility to
find proteins that change either in general in MDS, or just
within specific subgroups, could benefit our knowledge of
the molecular mechanisms and (patho)physiology of
MDS; and these results might thus influence the diagnosis,
treatment, and prognosis of the disease.
Although there are many proteomic methods and tech-
niques (e.g. chromatography, mass spectrometry, protein
biosensors [7-9]) that offer the possibility to look for pro-
tein alterations in biologic samples, 2-D electrophoresis is
usually the first choice despite some disadvantages. Never-
theless, there is no 'all purpose' proteomic method, and
each one has its own limitations. The preference for 2-D
electrophoresis in the first level of proteome exploration
results from the possibility to observe within the analysis,
not only proteins which change in the concentration, but
also those posttranslationally modified. It has been shown
that not only plasma protein levels change, but also the
presence of specific protein isoforms, which may be of
interest [10].
The aim of this proteomic study has been to explore the
plasma proteome of MDS patients with refractory anemia
and refractory anemia with ringed sideroblasts, and to
search for possible protein alterations in comparison with
healthy controls.
Methods
A total of 10 patient plasma samples (7 RA and 3 RARS
patient samples were included in the patient group further
denoted as RA-RARS) and 16 healthy controls have beeninvestigated in this proteomic study. The diagnosis of RA
and RARS was established according to the WHO classifi-
cation criteria [1]. The age of the patients ranged from 50
to 89 years, and there were 4 males (40%). Sex-matched,
healthy control donor age ranged from 21 to 35, and there
were 6 males (38%). All individuals tested agreed to par-
ticipate in the study on the basis of an informed consent.
All samples were obtained and analyzed in accordance
with the Ethical Committee regulations of the Institute of
Hematology and Blood Transfusion.
150 μl of diluted plasma (1:3 in MARS depletion
buffer) was used to deplete high-abundant plasma
proteins (MARS Hu-14 column; Agilent, Santa Clara,
CA, USA). This corresponded to the volume of 37.5 μl
of undiluted plasma used for each sample in this study.
Blood sample collection, plasma depletion, and sample
processing and storage were described in detail in our
previously published literature [5,6]. 2D electrophoresis,
image analysis, protein in-gel digestion, and mass spec-
trometry identification of proteins were also performed
as described in previous literature [10-12]. Briefly, isoelec-
tric focusing (IPG strips pI 4–7, 7.7 cm) was followed by
SDS-PAGE (8 × 10 cm, 10% resolving gel, 3.75% stacking
gel, 30 mA/gel), gels were scanned and processed with
Progenesis SameSpots software (Nonlinear Dynamics,
Newcastle upon Tyne, UK) that computed fold and
p-values of all spots using one way ANOVA analysis, and
Principal Component Analysis (PCA) was performed.
PCA was performed using only the spots of statistical
significance (based on 2D SDS-PAGE) employed for
protein identification. PCA was used to assess whether
grouping of patients and healthy controls based on the 2D
SDS-PAGE results reflects their stratification using clinical
diagnosis. No technical replicates were used for 2D
SDS-PAGE (non-pooled individual samples of patients and
donors were used only). MS/MS mass spectrometry (HCT
ultra ion-trap mass spectrometer with nanoelectrospray
ionization; Bruker Daltonics, Bremen, Germany) coupled to
a nanoLC system (UltiMate 3000; Dionex, CA, USA) was
used to perform MS analysis. Mascot (Matrix Science,
London, UK) was used for database searching (Swiss-Prot).
To eliminate peptide carry-over between HPLC separa-
tions, cleaning runs were performed before and after each
sample run. Two unique peptides (with a higher Mascot
score than the minimum for identification, p < 0.05) were
necessary to successfully identify a protein.
Relative label-free protein quantification was used to
compare tryptic peptide levels of alpha-2-HS-glycoprotein
(A2HSG) and retinol-binding protein 4 (RBP4) in the pa-
tient and control groups. Plasma proteins were digested
using modified protocols of acetonitrile precipitation of
plasma proteins and trypsin digestion, as described by Kay
et al. [13]. Briefly, to the 50 μl of sample plasma, 100 μl of
water, and 225 μl of acetonitrile were added, and then
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tions. After centrifugation (10 min, 12000 × g) 300 μl of
supernatant were transferred into a new Eppendorf tube
and completely dried. Pellets were then resuspended in
40 μl of 0.1 M NH4HCO3, 5 μl of 0.1 M DTT were added,
and the samples were incubated for 1 hr at 60°C. After the
samples cooled, 5 μl of 0.1 M iodoacetamide were added,
and the samples were incubated at room temperature in
the dark for 30 min. Trypsin digestion was started by
adding 4 μl of trypsin (200 μg/mL) in 50 mM acetic acid
and digested at 37°C overnight. The reaction was stopped
with the addition of 6.5 μl of 1% formic acid. Samples were
centrifuged (10 min, 12000 × g), filtered, and 20 μl of each
sample was loaded for LC-MS/MS analysis. Two A2HSG
peptides were monitored: HTFMGVVSLGSPSGEVSHPR
with precursor ion 694.7 m/z (charge 3+) and product ion
1109.5 m/z (y11); and EHAVEGDCDFQLLK with precur-
sor ion 830.9 m/z (2+) and product ion 1095.5 m/z (y9).
Peptides, precursor, and product ions were chosen on the
basis of MS/MS analysis (previous protein identification).
RBP4 peptides were the same as monitored in our pre-
vious publication describing plasma proteome changes
in RAEB-1 [6]: FSGTWYAMAK with precursor ion
589.3 m/z (2+) and product ion 785.3 m/z (y6); and
YWGVASFLQK with precursor ion 599.9 m/z (2+) and
product ion 849.5 m/z (y8). The nanoLC-MS/MS
system was the same as described above, but using a
60 min 0-70% acetonitrile non-linear gradient, with a
precursor selection window width of 2 Da. Extracted
ion chromatograms of the product ions were generated
with an ion m/z width of ± 0.5 Da, and peak areas wereFigure 1 Positions of significantly differing spots on a 2D gel. Position
RA-RARS patients were compared to healthy controls. A 2D gel of a patiencalculated after automatic integration using DataAnalysis
software (version 4.0; Bruker). Each sample was measured
twice, and a t-test was used for statistical analysis. All
sample results were validated according to MS/MS spectra
and retention times [14]. Blank runs were performed
before and after each sample run to eliminate peptide
carry-over.
Western blotting was performed as described previously
[10]. Briefly, proteins were transferred from a gel to a
PVDF membrane (10 V constant voltage for 1 hr), the
membrane was then incubated with a blocking buffer
(3% BSA in PBS) at 4°C overnight, rinsed, and incubated
with an anti-ITIH4 primary antibody (1:2,000 dilution)
(Abnova, Taipei, Taiwan) or an anti-RBP4 primary
antibody (1:2,000 dilution) (Abcam, Cambridge, UK), at
30°C for 45 min. Then the membrane was incubated
with the secondary antibody, rabbit anti-mouse IgG
antibody conjugated with peroxidase (for ITIH4 detec-
tion, 1:60,000 dilution) (Sigma-Aldrich, Prague, Czech
Republic) or goat polyclonal anti-rabbit IgG antibody
conjugated with peroxidase (for RBP4 detection,
1:10,000 dilution) (Abcam, Cambridge, UK), at 30°C for
45 min. After rinsing, a chemiluminescent substrate
(SuperSignal West Pico; Thermo Scientific, Waltham,
MA, USA) was added to the membrane for 5 min; and
an appropriate film exposure (Amersham Hyperfilm
ECL; GE Life Sciences, Piscataway, NJ, USA) was
performed. In total, 6 patient (3 RA and 3 RARS) and 6
sex-matched control samples were used for western
blotting; pooled patient and control samples were used
in addition.s of all 55 spots that were found to differ significantly (p < 0.05) when
t sample was used as the illustrative gel to display spot positions.
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using a commercial ELISA kit (Abcam, Cambridge, UK).
Sex-matched samples were measured according to manu-
facturer instructions; results were expressed as means ±
standard deviations. An unpaired t-test was used for
the comparison of plasma levels between RA-RARS
and patient groups.Results
2-DE gels of all samples were prepared for the experi-
ment, and scanned 2-DE gel images were divided into
patient (n = 10) and control (n = 16) groups. Comparing
these two groups we found 55 unique spots that differed
significantly (p < 0.05) in normalized volumes (Figure 1).
An example of four differing spots is shown in Figure 2.
Proteins in 49 spots were identified, which corresponded
to 39 different proteins. The list of all spots, including
ANOVA p-values, their multiplication (fold value), pro-
tein identification with the number of identified peptides
(unique peptides above the identity threshold score),
protein accession number (Swiss-Prot), and the sequenceFigure 2 An example of four differing spots. This figure represents an e
the logarithms of spot normalized volumes and their standard deviations fcoverage, is summarized in Table S1 (See Additional file 1:
Table S1).
Principal Component Analysis (PCA) was performed
making use of Progenesis SameSpots software employing
only the spots of statistical significance (based on 2D
electrophoresis). PCA showed an obvious separation of
all samples (2-DE gels) into two aggregates correspond-
ing to the patient (blue dots) and the control (pink dots)
groups, respectively (Figure 3).
In several spots (4, 9, 11, 12, 20, 27, 28, 41, 52, and 55),
fragments of inter-alpha-trypsin inhibitor heavy chain H4
(ITIH4) was observed. The molecular weights of the spots,
as estimated using 2-DE, corresponded to both 35 kDa
ITIH4 (spots 9, 11, 12, 20, 27, 28, and 41) and 70 kDa
ITIH4 (spots 4, 52, and 55) fragments. Moreover, when
comparing the sequences of ITIH4 identified peptides
(using MS/MS) in all spots with the observed fragmen-
tation, these peptides corresponded to both 35 and
70 kDa ITIH4 processed proteins. Significantly differing
spots containing uncleaved ITIH4 were not observed.
ITIH4 expression was assessed by western blot analysis;
a single band of more than 100 kDa of molecular weightxample of four differing spots (4, 9, 11 and 20). Expression profiles with
or RA-RARS patient and healthy control groups are shown.
Figure 3 Principal Component Analysis. Analysis was based on
spots that significantly differed according to the mentioned
statistical criteria (p < 0.05, ANOVA), and was performed to assess
whether grouping of patient and healthy controls based on 2D SDS-
PAGE reflects their stratification using classical clinical diagnosis. PCA
showed the separation of all samples into two aggregates that
corresponded to the RA-RARS (blue dots) and healthy control
groups (pink dots).
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uncleaved ITIH4, and no difference in ITIH4 expression
between the patient group (n = 6) and the control group
(n = 6) was observed. Using a monoclonal anti-ITIH4
antibody capable of detecting uncleaved ITIH4 and
70 kDa ITIH4 fragment, we did not observe the 70 kDa
ITIH4 fragment (the antibody did not act against the
35 kDa ITIH4 fragments).
RBP4 expression was assessed by western blot
analysis as described above; the same patient (n = 6)
and sex-matched control (n = 6) samples as for ITIH4
western blot analysis were used. No difference wasFigure 4 RBP4 and ITIH4 western blot analysis. Illustrations of 1D
SDS-PAGE/Western blot analysis of ITIH4 (the top section; 10%
resolving gel) and RBP4 (the bottom section; 15% resolving gel) are
shown. Lane 1: molecular weight marker (kDa); lanes 2 and 3:
RA-RARS patient (2) and control (3) pooled samples; lanes 4 to 7:
an example of individual male (4, 5) and female (6, 7) samples of
RA-RARS patients (4, 6) and healthy controls (5, 7).observed between patient RA-RARS and healthy con-
trol groups when comparing individual or pooled sam-
ples (Figure 4).
The data obtained using 2-DE cannot provide infor-
mation on the cause of the observed change – plasma
level change or posttranslational modification (PTM).
Comparisons of different peptides of the same protein
in two different groups (patient and control) using relative
quantification may provide additional information – at
least two unique fold change values in two different
peptides can prove the presence of PTM(s), which
would have influenced the results observed using 2-DE
(based on spot volume changes). As co-identification of
other proteins within a spot impairs data interpretation,
proteins with unique identifications in their spots,
together with satisfactory p-values, were considered for
relative quantification. Moreover, we focused on pro-
teins possibly related to MDS and its pathophysiology.
Two proteins satisfied these criteria, and relative label-
free protein quantification was used to compare tryptic
peptide levels of alpha-2-HS-glycoprotein (A2HSG) and
retinol-binding protein 4 (RBP4) in the patient (n = 10)
and control (n = 10) groups. The samples were the same
as used for 2-DE, and the control samples were sex-
matched with the patient group samples. Quantification
of A2HSG showed different fold change values for its
peptides; the average peak area value was increased by
more than two-fold in the MDS group (2.54-fold, no
statistical significance) when compared with the control
group for 694.7/1109.5, while there was no obvious
difference for 830.9/1095.5 (0.95-fold decrease) in the
MDS group when compared to the control group. For
RBP4 peptides, there were observed no differences
between the control and the patient sample groups for
both peptides: 0.92-fold and 1.12-fold difference for
589.3/785.3 and 599.9/849.5, respectively. The results
are summarized in Table 1.
The plasma level of A2HSG was measured for all
patient RA-RARS samples (n = 10) and sex-matched
control samples (n = 10): 471 ± 38 μg/ml (RA-RARS)
and 562 ± 28 μg/ml (control). This corresponds to 1.2-fold
decrease of A2HSG plasma level in the patient group.
The difference was found to be statistically significant
(t-test, p = 1.3 × 10-5).
Discussion
This paper represents the first report on plasma proteome
changes using 2-DE in MDS patients with RA and RARS
subgroups of MDS. Both RA and RARS are closely related
subgroups of MDS, and according to Malcovati et al. [15]
are characteristic with a very low risk of transformation
into acute myeloid leukemia and good predicted survival.
According to WHO Classification-Based Prognostic
Scoring System (WPSS) for MDS [15], there are different
Table 1 Relative label-free quantification of proteins
Protein Peptide sequence Precursor ion [m/z] Precursor charge Product ion [m/z] Product ion fold (MDS/N)
A2HSG HTFMGVVSLGSPSGEVSHPR 694.7 3+ 1109.5 y11 2.54
A2HSG EHAVEGDCDFQLLK 830.9 2+ 1095.5 y9 0.95
RBP4 FSGTWYAMAK 589.3 2+ 785.3 y6 0.92
RBP4 YWGVASFLQK 599.9 2+ 849.5 y8 1.12
A2HSG (alpha-2-HS-glycoprotein), RBP4 (retinol-binding protein 4), no fold value was found to be significantly different.
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low risk group. Our previously studied groups RCMD [5]
and RAEB-1 [6] belong to low and intermediate risk
groups, respectively. Therefore, including this study, there
are three different MDS risk groups that can be compared
so far, and it is a future task to explore proteome changes
in the high risk RAEB-2 subgroup. When the results of all
of the three so-far-studied MDS subgroups are compared
in general, it is interesting that there is no substantial
difference in the numbers of observed changes; there were
61, 56, and 55 significant changes observed in RCMD,
RAEB-1 and RA-RARS, respectively. Despite differences
in the number of samples in the studied subgroups, we
expected an increase in the number of observed changes
in plasma proteome correlating to an increasing WPSS
score of the studied subgroups. It seems that it is rather
an increase in ‘a depth of changes’ than in the number of
changes. Thus, it is important to look for changes in the
initial step (selection of candidate proteins); however, it
seems probably even more important to profile protein
changes (whether caused by protein level changes or
PTMs) in different MDS subgroups in the future. Another
issue that should be noted is the choice of the control
group, which differs in age range when compared to the
MDS patient group. Optimally, the control group should
match for as many parameters as possible. As MDS
usually occurs in elderly patients, the control group should
be of similar age range. However, this matching may
contribute to other limitations – the primary difficulty is
to find healthy individuals of older age who do not suffer
from other diseases (diabetes, hypertension etc.) which
may significantly affect the obtained results. Further, MDS
is not exclusively limited to elderly patients only. Consid-
ering that, we decided to compare our patient group with
a healthy control group of lower age range to possibly
observe all the changes that would occur. Moreover, we
used the same characteristic for the control group as in
our previous proteomic studies of MDS patients [5,6] to
be consistent in the results and their interpretation.
When compared to our previous proteomic studies
characterizing changes in the plasma proteome of patients
with RCMD [5] and RAEB-1 [6], there is agreement in
some results. One of the most evident is the presence of
fragmentation of the ITIH4 protein. Normalized volumes
of spots containing ITIH4 fragments corresponding to35 kDa ITIH4 were decreased in RA-RARS, as well as
in both the RCMD and RAEB-1 groups, when compared
to the control groups. A 70 kDa ITIH4 fragment was
identified in the RA-RARS and RCMD groups with the
same characteristics of the changes of spot volume
(decrease); however, it was only co-identified in spots
together with other proteins and thus its interpretation
would be speculative. It remains a question whether
ITIH4 fragmentation (or modification) could be MDS
specific – comparisons of MDS subgroups together with
different control groups (non-MDS cytopenias etc.)
would be welcome. Even though ITIH4 fragmentation
has been found to be potentially associated with MDS
[3], it has been also found in other malignant diseases
[16,17]. Therefore, ITIH4 fragments could in general be
considered as a cancer marker, but not as a marker
specific to MDS. Nevertheless, there should be other
more specific proteomic data to definitively draw such
conclusions; the fragmentation pattern should be eluci-
dated, as well as the possible influence of PTMs. For
example, the 70 kDa ITIH4 fragment was not observed
in RA-RARS, RAEB-1, or RCMD (using western blot
analysis) even though the antibody used should have
detected it. This could suggest that the fragmentation
did not correspond to that induced by kallikrein (which
processes the plasma ITIH4 and cleaves it to produce
35 and 70 kDa fragments). This notion may be sup-
ported by the fact that fragments found in proteomic
study by Chen et al. [3] using mass spectrometry plasma
profiling were smaller than 35 or 70 kDa. Inflammation
could be another factor that influences ITIH4 alter-
ations, as this protein is known to belong to the group
of acute phase proteins.
A2HSG has been found to be related to several func-
tions – endocytosis, opsonization, or bone tissue forma-
tion [18-20]. This protein has been localized in the bone
marrow matrix, and is believed to influence bone
marrow development and function [21]. It has been also
shown that A2HSG is linked to inflammation, and is
one of the acute phase proteins, which may be regulated
either positively (in some cases) or negatively during an
acute phase reaction [22-24]. A2HSG is also supposed
to be involved in diabetes [25] and insulin resistance
[26], the regulation of protease activity [27], the develop-
ment of atherosclerosis [28], etc. It has been shown that
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is suspected to be involved in the pathophysiology of
malignant diseases [29]. Anti-A2HSG antibodies have
been found in the serum of breast cancer patients [30]. In
spite of many diseases and processes of which A2HSG is
supposed to be involved in, the exact mechanisms of
A2HSG function in (patho)physiology are not known. The
connection of A2HSG with cytokines, inflammation, and
the bone marrow (and its development) could be of inter-
est in relation to MDS. However, it is difficult to speculate
on the possible role of A2HSG in MDS, especially when
taking into account that plasma levels may be either
decreased or increased due to different conditions [31]. In
this study, A2HSG has been identified in four spots, with
unique identifications in two of them (spots 3 and 29).
Normalized volumes of both the spots were decreased (2.3
and 1.4-fold) in the RA-RARS group. This corresponds to
the observed decrease of A2HSG plasma level when abso-
lute quantification was performed (fold 1.2), however, this
fold value corresponds rather to 1.4-fold value as observed
in the spot 29 than to 2.3-fold in the spot 3. The presence
of A2HSG in a few spots changing with different fold
values indicates PTM(s); the discrepancy between the
changes observed in 2-DE data and absolute quantification
further supports this assumption. Finally, relative quantifi-
cation results showed that while one of the two estimated
A2HSG peptides was not altered at all (0.95-fold change),
the second peptide was increased more than two-fold in
the MDS group (2.54-fold). This also suggests the pres-
ence of PTM(s); however, the change was not found to be
statistically significant. In a study by Petrik et al. [32],
A2HSG was found to be a serum marker of survival in
patients with glioblastoma; moreover, A2HSG serum level
change was not related to comorbidity and inflammation
(it has been shown that a decrease in A2HSG levels corre-
lated with the degree of tumor malignancy). The authors
also point out that A2HSG was not a glioblastoma specific
marker, as there was correlation with the malignancy of
other tumor types. As this protein (the decrease in
plasma/serum protein levels) mirrors the degree of malig-
nancy found in different tumor types and we have
observed decreases of spot normalized volumes in MDS
patients, the future task should be profiling the change
(and possible correlation) of A2HSG plasma levels in pa-
tients with different MDS subgroups, according to their
survival and the degree of malignancy. This was not
possible to perform yet, due to the limited number of
samples. It is also interesting that the change in A2HSG
in the study by Petrik et al. [32] was found in the
A2HSG B-chain, while in our study the A-chain and the
connecting peptide were identified (both chains are
linked by disulfides, whose bonds are disrupted during
2-DE sample analysis; the B-chain Mw is less than
3 kDa, and therefore could not be detected in our studyusing 2-DE). As Petrik et al. further estimated serum
levels using the turbidimetric method and polyclonal
antibodies, the decrease in A2HSG serum level should
correspond to the whole protein molecule. Neverthe-
less, the authors also speculated on the possible influ-
ence of PTMs (in terms of B-chain and the whole
A2HSG molecule); and our study suggests that there
could be such a factor (PTM) according to the compari-
son of 2-DE, absolute and relative quantification results.
Another factor that could influence the A2HSG plasma/
serum level is proteolytic degradation of the protein; the
presence of A2HSG fragments in serum (depending on
the protein preparation) has been described in existing
literature [22]. However, Petrik et al. [32] has proven
that the A2HSG level in serum is stable for at least two
weeks at 4°C, including after several freeze-thaw cycles.
Retinol-binding protein 4 (RBP4) is a specific carrier
protein for retinol [33]; it is associated with variables
related to insulin resistance [34]; is involved in inflam-
mation and related to liver function; and its serum level
is reduced in critically ill patients [35]. Using 2-DE, a
change (decrease) in RBP4 was also observed in the
group of chemosensitive patients with multiple myeloma,
which were treated with bortezomib-based regimens,
when compared with patients resistant to chemotherapy
[36], and also in the sera of epithelial ovarian cancer
patients [37]. It has also been shown that an increased
ratio of unbound to bound (binding to retinol) RBP4 levels
may induce apoptosis in renal and endothelial cells [38]. It
is known that retinoids (retinol, etc.) are involved in cell
differentiation and in tumor development, probably due to
the disruption of retinoid signaling [39]. Some anticancer
agents may induce RBP4 expression in vivo [40]. In our
previous proteomic study of the RAEB-1 subgroup [6],
RBP4 was identified in a spot with a decreased normalized
volume in patients with MDS, compared to healthy con-
trols. Relative label-free quantification of RBP4 peptides
was performed; the influence of PTM was not proven; and
it was speculated that a RBP4 plasma level change was
possibly specific for the RAEB-1 subgroup. In this study,
RBP4 was uniquely identified in one spot (spot 30) with
its normalized volume decreased in the patient group by
1.4-fold. Thus, the results obtained by 2-DE are in
accord with the RAEB-1 subgroup. Nevertheless, when
results of relative label-free quantification of RBP4 pep-
tides are compared, some differences may be observed.
Relative quantification was performed using the same
peptides and conditions as in the previously studied
RAEB-1 subgroup. Even though there were no differ-
ences between the patient and the healthy control
groups observed in both subgroups (i.e., no PTM in the
monitored peptides was proven), it is remarkable that
there was no difference in peptide levels in RA-RARS
observed at all (0.92 and 1.12-fold difference between
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decrease in the same peptide levels in RAEB-1 (2.33 and
3.25-fold). This strongly indicates an influence of PTM(s)
of RBP4 in the RA-RARS subgroup with the position(s)
in other (not monitored) peptides. It also suggests that
the results observed in the RAEB-1 subgroup were not
caused by RBP4 plasma level change only, as it was
speculated in the RAEB-1 study [6], but it is likely that
there was an influence of both protein modification and
level changes. In this study, RBP4 expression estimated
by western blot analysis showed no obvious difference.
Therefore, western blot analysis supports the notion
that RBP4 was influenced by PTM(s). The RBP4 results
have shown that although there are almost identical
observations using 2-DE, it is necessary to use other
methods to ‘see beyond’ as the similar results may be
caused by different factors. It has also been shown that
mass spectrometry-based relative label-free quantifica-
tion of peptides may provide additional useful infor-
mation, in spite of monitoring only a limited number
of peptides.Conclusions
In conclusion, this is the first report on plasma proteome
changes, using 2D electrophoresis, in MDS patients with
refractory anemia and refractory anemia with ringed
sideroblasts. When comparing results to our previous
proteomic studies of other MDS subgroups (refractory
cytopenia with multilineage dysplasia and refractory anemia
with excess blasts subtype 1), there are agreements in some
results, especially in changes in the composition or modifi-
cation of fragments of inter-alpha-trypsin inhibitor heavy
chain H4 protein. Further, agreement in 2D electrophoresis
results for retinol-binding protein 4 was observed when
compared to our previous study of refractory anemia with
excess blasts subtype 1. However, mass spectrometry
based relative label-free quantification of retinol-binding
protein 4 peptides has shown that there are differences in
the PTM(s) of this protein between the two MDS sub-
groups. The relative label-free quantification (together
with absolute quantification and 2D electrophoresis data)
also suggests a possible role of PTM(s) of alpha-2-HS-
glycoprotein, a protein related to bone marrow develop-
ment and function, in MDS patients with refractory
anemia and refractory anemia with ringed sideroblasts.Additional file
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